Page last updated: 2024-11-07

zinc coproporphyrin iii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Zinc coproporphyrin III is a porphyrin compound that contains zinc as its central metal ion. It is a derivative of coproporphyrin, a natural precursor to heme. Zinc coproporphyrin III is known to exhibit fluorescence properties, and its presence in biological samples can be detected using techniques like fluorescence spectroscopy. Research into this compound focuses on its potential applications in areas like bioimaging, sensing, and photodynamic therapy. It is also studied in the context of its role in various metabolic processes and its potential association with certain diseases. The synthesis of zinc coproporphyrin III typically involves reacting coproporphyrin with zinc salts under specific conditions.'

coproporphyrin III: RN given refers to unlabeled parent cpd; see also record for coproporphyrin I [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID114935
CHEBI ID27609
SCHEMBL ID3765609
SCHEMBL ID498526
SCHEMBL ID21940536
MeSH IDM0088060

Synonyms (29)

Synonym
CHEBI:27609
3,8,13,17-tetramethylporphyrin-2,7,12,18-tetrapropanoic acid
coproporphyrin iii
C05770
14643-66-4
3-[(5z,10z,14z,19z)-8,12,17-tris(2-carboxyethyl)-3,7,13,18-tetramethyl-21,23-dihydroporphyrin-2-yl]propanoic acid
coproporphyrin iii tetrasodium
zinc coproporphyrin iii
SCHEMBL3765609
3-[8,13,18-tris(2-carboxyethyl)-3,7,12,17-tetramethyl-21,24-dihydroporphyrin-2-yl]propanoic acid
coproporphyrin iii dihydrochloride
21h,23h-porphine-2,7,12,18-tetrapropanoic acid, 3,8,13,17-tetramethyl-
3,8,13,17-tetramethyl-21h,23h-porphine-2,7,12,18-tetrapropanoic acid
zincphyrin
SCHEMBL498526
JWFCYWSMNRLXLX-UJJXFSCMSA-N
XNBNKCLBGTWWSD-UHFFFAOYSA-N
AS-72746
koproporphyrin iii
koproporphyrin
DTXSID50904307
SCHEMBL21940536
coproporphyriniiidihydrochloride
Q27103223
AKOS037647184
3,3',3'',3'''-(3,8,13,17-tetramethylporphyrin-2,7,12,18-tetrayl)tetrapropanoic acid
DTXSID20864520
coproporphyriniii
ETX4TFE9GJ

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Zinc-coproporphyrin III (Zincphyrin) acts efficiently as a photodynamic therapy (PDT) agent in mice, while it shows no tumor cell-killing activity in vitro and has a high LD50 (low toxicity) in mice."( Production of singlet oxygen on irradiation of a photodynamic therapy agent, zinc-coproporphyrin III, with low host toxicity.
Arakane, K; Matsumoto, K; Nagano, T; Okura, I; Urano, Y; Yamamoto, M, 2003
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" Population pharmacokinetic analysis was conducted to assess whether MTX clearance (MTXCL) was associated with the basal UCP I/(I + III) ratio, its variation during MTX infusion, the DIS or other common covariates."( Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.
Benz-de Bretagne, I; Choquet, S; Gyan, E; Hoang-Xuan, K; Houillier, C; Hulot, JS; Le Gouge, A; Le Guellec, C; Lissandre, S; Zahr, N, 2014
)
0.4
"Despite a recent expansion in the recognition of the potential utility of coproporphyrin (CP) as an endogenous biomarker of organic anion-transporting polypeptide (OATP) 1B activity, there have been few detailed studies of CP's pharmacokinetic behavior and an overall poor understanding of its pharmacokinetic fate from tissues and excretion."( Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
Fancher, RM; Gan, J; Gu, X; Hong, Y; Lai, Y; Shen, H; Sinz, M; Tian, Y; Wang, L, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" Collectively, we conclude that CP-I and CP-III in plasma and urine can be appropriate endogenous biomarkers specifically and reliably reflecting OATP inhibition, and thus the measurement of these molecules can serve as a useful tool to assess OATP drug-drug interaction liabilities in early clinical studies."( Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.
Cheng, Y; Dai, J; Date, O; Gaud, N; Holenarsipur, VK; Humphreys, WG; Lai, Y; Langish, R; Mandlekar, S; Marathe, P; Murugesan, S; Rajanna, P; Selvam, S; Shen, H; Shipkova, P, 2016
)
0.43
" These data demonstrate the potential of CP-I and CP-III as endogenous biomarkers to predict the drug-drug interaction (DDI) related to hepatic OATP1B inhibition."( Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions.
Diels, L; Dillen, L; Kunze, A; Njumbe Ediage, E; Snoeys, J; Verhaeghe, T; Vroman, A, 2018
)
0.48
"Coproporphyrin (CP) I and III have recently been proposed as endogenous clinical biomarkers to predict organic anion-transporting polypeptide 1B (OATP1B)-mediated drug-drug interactions (DDIs)."( Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
Dillen, L; Ediage, EN; Kunze, A; Monshouwer, M; Snoeys, J, 2018
)
0.48
" Furthermore, CPI and CPIII plasma concentrations were determined from participants of three independent clinical trials who were administered with either a strong, moderate, or mild clinical OATP1B inhibitor."( Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
Dillen, L; Ediage, EN; Kunze, A; Monshouwer, M; Snoeys, J, 2018
)
0.48
"A robust UHPLC-MS/MS assay was developed and validated for CP-I and CP-III in plasma, and is currently applied to clinical studies to confirm suitability of Coproporphyrins as a potential substitute for drug-drug interaction study."( UHPLC-MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions.
Burrrell, R; Easter, J; Kadiyala, P; Kandoussi, H; Lai, Y; Langish, R; Marathe, P; Mariannino, T; Paterson, P; Pillutla, R; Santockyte, R; Shah, K; Shen, H; Shipkova, P; Zeng, J; Zhang, Y, 2018
)
0.48

Dosage Studied

ExcerptRelevanceReference
" Significant dose-response relationship was observed between control and treatment groups after 1, 4, 24, 32, 48, 56, 88, 96 and 104 weeks."( Urinary arsenic and porphyrin profile in C57BL/6J mice chronically exposed to monomethylarsonous acid (MMAIII) for two years.
Krishnamohan, M; Lam, PK; Moore, MR; Ng, JC; Qi, L, 2007
)
0.34
" Moreover, CP-I and CP-III plasma levels in human subjects dosed with a clinically confirmed OATP inhibitor were significantly increased compared to their baseline levels."( Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions.
Diels, L; Dillen, L; Kunze, A; Njumbe Ediage, E; Snoeys, J; Verhaeghe, T; Vroman, A, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (116)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (21.55)18.7374
1990's25 (21.55)18.2507
2000's21 (18.10)29.6817
2010's33 (28.45)24.3611
2020's12 (10.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.88 (24.57)
Research Supply Index4.84 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (5.04%)5.53%
Reviews4 (3.36%)6.00%
Case Studies9 (7.56%)4.05%
Observational0 (0.00%)0.25%
Other100 (84.03%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]